Publication | Closed Access

A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

Metastatic Breast CancerBreast OncologyPhase IiSingle-arm TrialMedicineBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation Oncology